These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2156 related articles for article (PubMed ID: 27930644)
1. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
2. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Campbell MT; Siefker-Radtke AO; Gao J Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904 [TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Therapies in Prostate Cancer. Goswami S; Aparicio A; Subudhi SK Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907 [TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Therapy in Melanoma. Callahan MK Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901 [TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Therapy in Head and Neck Cancers. Msaouel P; Massarelli E Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906 [TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in breast cancer: hype or promise? McArthur HL Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806 [No Abstract] [Full Text] [Related]
7. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Blockade in Breast Cancer Therapy. Bu X; Yao Y; Li X Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694 [TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Ring KL; Pakish J; Jazaeri AA Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905 [TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
11. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Shin DS; Ribas A Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841 [TBL] [Abstract][Full Text] [Related]
13. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Hu ZI; Ho AY; McArthur HL Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141 [TBL] [Abstract][Full Text] [Related]
14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related]
15. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]